Table 1.

Eligibility criteria

Category	Inclusion criteria	Exclusion criteria
Population	A population including OA patients
Intervention	Any pharmacological intervention given for the treatment of OA	COX2 inhibitors removed from the market (e.g. rofecoxib)
Comparators	Any other strategy, including other pharmacological intervention, usual care, or ‘doing nothing’
Study design	Full health economic evaluations (CEAs) defined by the presentation of at least one incremental cost-effectiveness ratio (ICER) or that found an intervention to be dominant	Partial health economic evaluations (e.g., cost minimization and cost consequence studies were excluded if they did not also include an ICER outcome); case studies; commentaries; editorials; letters; conference abstracts; research protocols; animal studies
Language	English
Publication date	Published before 3 November 2021

OA osteoarthritis, CEA cost-effectiveness analysis, ICER incremental cost-effectiveness ratio